CGIM
REGN icon

Capital Group Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital Group Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83M Hold
2,938
– – 0.28% 85
2026
Q1 		$2.27M Buy
2,938
+71
+2% +$54.4K 0.39% 69
2025
Q4 		$2.21M Sell
2,867
-3,089
-52% -$2.1M 0.36% 71
2025
Q3 		$3.35M Sell
5,956
-1,109
-16% -$627K 0.56% 50
2025
Q2 		$3.71M Sell
7,065
-1,860
-21% -$1.04M 0.66% 49
2025
Q1 		$5.66M Buy
8,925
+182
+2% +$125K 1.16% 24
2024
Q4 		$6.23M Buy
8,743
+1,275
+17% +$1.07M 1.18% 22
2024
Q3 		$7.85M Buy
7,468
+31
+0.4% +$34.5K 1.58% 14
2024
Q2 		$7.82M Sell
7,437
-702
-9% -$681K 1.69% 13
2024
Q1 		$7.83M Sell
8,139
-5,453
-40% -$5.19M 1.4% 14
2023
Q4 		$11.9M Sell
13,592
-12,127
-47% -$9.99M 1.25% 17
2023
Q3 		$21.2M Sell
25,719
-3,630
-12% -$2.85M 1.38% 17
2023
Q2 		$21.1M Buy
29,349
+1,444
+5% +$1.11M 1.05% 29
2023
Q1 		$22.9M Sell
27,905
-13,416
-32% -$10.1M 1.23% 21
2022
Q4 		$29.8M Buy
+41,321
New +$30.5M 1.15% 29

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital Group Investment Management's REGN Position: Q2 2026 in Review

Capital Group Investment Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 2,938 shares worth $1.83M. The position accounts for 0.28% of the portfolio, ranked #85.

Capital Group Investment Management first reported a position in REGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $29.8M in Q4 2022. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Capital Group Investment Management held 2,938 shares of Regeneron Pharmaceuticals worth $1.83M as of Q2 2026.
  • Capital Group Investment Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.28% of Capital Group Investment Management's portfolio in Q2 2026, its #85 holding.
  • Capital Group Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Capital Group Investment Management's Regeneron Pharmaceuticals position peaked at $29.8M in Q4 2022.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Capital Group Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.